Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04952467 | Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101 | PHASE1 | COMPLETED | 6 | — | — | Jul 14, 2021 | Oct 4, 2021 | Jan 14, 2022 | 1 | United Kingdom |
Cumulative amount of total radioactivity excreted in urine and feces combined (CumAe(total)) and expressed as a % of the radioactive dose administered (Cum%Ae(total)) following oral administration of 14C-XEN1101
| Arm | Type | Description |
|---|---|---|
| Drug: (14C)-XEN1101 | EXPERIMENTAL | Subjects will receive oral 14C-XEN1101 under fed conditions. |
| Name | Type | Description |
|---|---|---|
| 14C-XEN1101 | DRUG | Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101 |
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kg/m2 * Must be willing and able to communicate and participate in the whole study * Provide written informed consent * Adhere to the specified contraception requirements Key Exclusion Criteria: * Subjects who have received any inves...